Similar articles

• The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.

  Demarquay D, Coulomb H, Huchet M, Lesueur-Ginot L, Camara J, Lavergne O, Bigg D. Demarquay D, et al. Ann N Y Acad Sci. 2000;922:301-2. doi: 10.1111/j.1749-6632.2000.tb07048.x. Ann N Y Acad Sci. 2000. PMID: 11193906 No abstract available.
• BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.

  Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, Huchet M, Coulomb H, Bigg DC. Lavergne O, et al. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2599-602. doi: 10.1016/s0960-894x(99)00428-x. Bioorg Med Chem Lett. 1999. PMID: 10498216
• The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.

  Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly C, Camara J, Bigg DC. Demarquay D, et al. Anticancer Drugs. 2001 Jan;12(1):9-19. doi: 10.1097/00001813-200101000-00003. Anticancer Drugs. 2001. PMID: 11272292
• [Homocamptothecins--novel promising anticancer drugs as inhibitors of topoisomerase I].

  Yang S, Zhang WN. Yang S, et al. Yao Xue Xue Bao. 2004 May;39(5):396-400. Yao Xue Xue Bao. 2004. PMID: 15338888 Review. Chinese. No abstract available.
• Topoisomerase I inhibitors: topotecan and irenotecan.

  Creemers GJ, Lund B, Verweij J. Creemers GJ, et al. Cancer Treat Rev. 1994 Jan;20(1):73-96. doi: 10.1016/0305-7372(94)90011-6. Cancer Treat Rev. 1994. PMID: 8293429 Review. No abstract available.